ABO-incompatible bone marrow transplantation.
In the past 10 years 201 HLA-identical bone marrow transplantations (BMT) were performed with major ABO incompatibility in 41 (20%) and minor ABO incompatibility in 35 (18%) patients. ABO compatibility between donor and recipient showed no influence on granulocyte and platelet recovery after BMT. Erythrocyte reconstitution was significantly (p < 0.01) delayed for about 1 week in major ABO-incompatible BMT. In addition, a pure red cell aplasia lasting for 2-5 months occurred in 6 out of 21 blood group 0 patients who received transplants of group A. The rate of graft rejection, incidence of graft-versus-host disease as well as the leukemic relapse rate were similar in ABO-compatible and ABO-incompatible BMT. The probability of a 10-year survival after BMT is independent of ABO compatibility between donor and recipient.
Wiesneth
M
M
Red Cross Blood Bank Ulm, FRG.
Hertenstein
B
B
Bunjes
D
D
Schmeiser
T
T
Maccari
B
B
Northoff
H
H
Laasch
H
H
Heit
W
W
Arnold
R
R
Heimpel
H
H
D000017:ABO Blood-Group System / Q000235:genetics*; D000293:Adolescent; D000328:Adult; D001787:Blood Group Incompatibility / Q000235:genetics / Q000276:immunology*; D016026:Bone Marrow Transplantation / Q000276:immunology*; D005260:Female; D006084:Graft Rejection / Q000235:genetics / Q000276:immunology; D006086:Graft vs Host Disease / Q000235:genetics / Q000276:immunology; D006410:Hematopoiesis / Q000276:immunology; D006461:Hemolysis / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D008297:Male; D008875:Middle Aged; D012010:Red-Cell Aplasia, Pure / Q000235:genetics / Q000276:immunology; D012189:Retrospective Studies
D000017:ABO Blood-Group System